Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Shares Outstanding (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Shares Outstanding for 7 consecutive years, with $57.6 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 25.8% to $57.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57.6 million through Dec 2025, up 25.8% year-over-year, with the annual reading at $57.6 million for FY2025, 25.8% up from the prior year.
  • Shares Outstanding for Q4 2025 was $57.6 million at 4D Molecular Therapeutics, up from $46.8 million in the prior quarter.
  • The five-year high for Shares Outstanding was $57.6 million in Q4 2025, with the low at $26.7 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $40.1 million, with a median of $42.4 million recorded in 2023.
  • The sharpest move saw Shares Outstanding soared 418.75% in 2021, then decreased 10.05% in 2025.
  • Over 5 years, Shares Outstanding stood at $32.2 million in 2021, then increased by 1.25% to $32.6 million in 2022, then skyrocketed by 32.02% to $43.1 million in 2023, then increased by 6.31% to $45.8 million in 2024, then rose by 25.8% to $57.6 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $57.6 million, $46.8 million, and $46.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.